Cryoport, Inc. provides integrated, temperature-controlled supply chain solutions for the life sciences industry, with a primary focus on the cell and gene therapy market. The company serves biopharmaceutical and pharmaceutical companies, animal health organizations, reproductive medicine providers, academic institutions, research facilities, and government agencies across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Its operations are divided into two reportable segments: Life Sciences Services and Life Sciences Products. The Life Sciences Services segment offers advanced logistics, biostorage, kitting, labeling, clinical sample management, and cryopreservation services for starting materials. The Life Sciences Products segment involves the design and manufacture of cryogenic systems, including freezers, dewars, and transport systems. Key business units include Cryoport Systems, which handles bio-logistics and bio-services; CryoGene, which provides long-term biostorage; and MVE Biological Solutions, which manufactures cryogenic equipment. The company utilizes the Cryoportal digital logistics management platform and the Chain of Compliance framework to ensure regulatory adherence and material integrity. Cryoport maintains a strategic partnership with DHL Supply Chain following the divestiture of its CRYOPDP specialty courier business.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Integrated Freight & Logistics Homepage cryoportinc.com
Sector Industrials IR page ir.cryoportinc.com
Tags
temperature-controlled logistics, cell and gene therapy, biostorage, cryogenic systems, biopharmaceutical supply chain, reproductive medicine, animal health, clinical trial logistics, chain of compliance, cryopreservation, Cryoport Systems, CryoGene, MVE Biological Solutions, MVE, Cryoportal, IntegriCell, CryoVerse, Smartpak, Tec4med, CRYOPDP
Press page ir.cryoportinc.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 1.01B
Market cap (USD) $ 1.01B
P/E -24.95
PEG —
P/BV 2.09
P/S 5.25
P/OCF 91.82
P/FCF -53.70
Dividend yield —
Turnover / mcap —
Returns  
ROE 17.3%
ROI 11.4%
ROIC -4.0%
Profit margin 44.4%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 37.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 20
Quality score -5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Revenue 176.177M 228.385M 233.255M 237.277M 222.608M 78.696M 33.942M 19.626M 11.954M 5.882M 3.935M 2.66M 1.101M 555.637K 475.504K 117.956K — —
Net profit 78.301M -114.756M -99.587M -37.333M -275.528M -32.693M -18.331M -9.556M -7.899M -9.82M -7.027M -19.565M -6.382M -7.833M -6.152M -5.652M -16.705M -4.564M
Free cash flow -25.019M -33.577M -39.542M -23.958M -15.756M -23.784M -6.66M -6.266M -5.298M -7.425M -4.198M -4.52M -4.941M -7.043M -5.153M -2.885M -2.645M -2.002M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Share price 9.6 7.78 15.49 17.35 59.17 43.88 16.46 11.03 8.59 2.03 0.71 — — — — — — —
Price performance 12m 0.23 -0.5 -0.11 -0.71 0.35 1.67 0.49 0.28 1.65 1.85 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.2M 1.63M 3.54M 7.1M 31.4M 39.4M 43.9M 42.1M 45.8M 33.4M
↳ YoY growth +93.8% +36.0% +118.0% +100.3% +342.0% +25.6% +11.3% -4.1% +8.8% -27.1%
↳ 5y CAGR +70.2% +51.9% +41.0% +77.1% +119.4% +101.2% +93.3% +64.0% +45.2% +1.2%
Lease liabilities (USD) — — 56,347 4.8M 14.7M 21.8M 28.8M 36M 51.2M 44.4M
Cash and deposits (USD) 4.52M 15M 37.3M 47.2M 36.9M 139M 36.6M 46.3M 45.3M 250M
Intangible assets (USD) 5,000 90,646 137,220 5.18M 214M 201M 191M 194M 170M 138M
Right-of-use assets (USD) — — 0.00 4.46M 14M 20.7M 26.9M 32.7M 47.2M 39.7M
Cash flow detail
Operating cash flow (USD) -5.72M -3.58M -3.35M -1.32M -14.9M 8.13M -1.85M -757,000 -16.3M -8.58M
Purchases of property, plant and equipment (USD) -1.06M -1.71M -2.91M -5.34M -8.92M -23.9M -22.1M -38.8M -17.3M -16.4M
Purchases of intangible assets (USD) -5,000 -85,646 -46,574 -73,608 -200,000 -255,000 -614,000 -871,000 -1.13M -1.23M
Change in inventories (cash effect) (USD) -74,895 -25,297 -105,718 -253,447 1.32M -5.98M -14.2M 1.51M 3.25M -2.19M
Change in payables (cash effect) (USD) 51,320 123,249 405,074 570,477 4.25M -398,000 -6.48M -2.77M -76,000 -3.46M
Share buybacks (cash effect) (USD) — — — — 0.00 0.00 -38M — — -10M
Interest paid (cash effect) (USD) -9,534 -4,744 -637 -707,150 -1.82M -3.3M -3.63M -3.4M -2.69M -1.63M
Income taxes paid (cash effect) (USD) -5,673 -5,143 -19,954 -13,888 -60,000 -1.32M -1.98M -1.46M -1.42M -1.94M
Share-based compensation (USD) 3.12M 3.55M 5.48M 16.5M 8,916 15.3M 20.1M 22.8M 19.7M 10.1M
Free cash flow (OCF - PPE - intangibles) (USD) -6.79M -5.38M -6.31M -6.73M -24M -16M -24.6M -40.4M -34.7M -26.3M
Income detail
Research and development expense (USD) 598,106 1.21M 1.84M 3.74M 9.48M 16.8M 15.7M 18M 17.7M 17M
↳ 5y CAGR +95.0% +67.1% +57.9% +36.5% +12.4%
Total comprehensive income (USD) — -7.9M -9.55M -18.4M -27.3M -282M -70.6M -91.1M -110M 95.7M
Comprehensive income to owners (USD) — -7.9M -9.55M -18.4M -27.3M -282M -70.6M -91.1M -110M 95.7M
Provision for credit losses (USD) 2,503 11,646 40,215 42,085 197,000 26,000 234,000 — — —
Credit cost ratio (credit losses / average receivables) (%) 0.3% 0.8% 1.6% 0.8% 1.0% 0.1% 0.6% — — —
Reported Mar 8, 2018 Mar 13, 2019 May 9, 2019 May 8, 2020 Feb 28, 2023 Feb 28, 2023 Feb 28, 2023 Mar 13, 2024 Mar 7, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 05, 2026 4:05 pm EST Download as PDF

Related Documents

Earnings Webcast AUDIO

10-Q HTML PDF

XBRL ZIP

  • Third quarter revenue grew 14% year-over-year to $50.2 million
  • Commercial Cell and Gene Therapy revenue increased 20% year-over-year
  • Supporting a record 788 global clinical trials and 23 commercially approved cell and gene therapies as of September 30, 2026
  • Raises full-year 2026 revenue guidance to $197 million - $199 million

NASHVILLE, Tenn., Nov. 5, 2026 /PRNewswire/ -- Cryoport, Inc.  (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2026.

Cryoport logo 2024

Jerrell Shelton, CEO of Cryoport, stated, "Cryoport delivered third quarter revenue of $50.2 million, reflecting continued momentum across our core cell and gene therapy (CGT) business. Revenue from commercial CGT clients increased 20% year over year, BioStorage/BioServices revenue expanded 25%, and total Life Sciences Services revenue grew 18%, underscoring the strength of our integrated platform and the growing demand for our solutions. These results reflect both the increasing number of patients worldwide receiving CGT treatments and the continued adoption of our end-to-end temperature-controlled supply chain solutions. We also achieved 8% year over year growth in Life Sciences Products revenue, supported by MVE Biological Solutions' (MVE) position as the global market leader in cryogenic systems.

"During the quarter, we further strengthened our leadership position within the CGT ecosystem, ending the period supporting 23 commercial therapies and a record of 788 clinical trials worldwide. Our integrated platform, disciplined execution, and growing utilization of our Global Supply Chain Center Network continue to enhance scalability and operating leverage, advancing our progress toward sustained profitability. This momentum was reflected in our positive adjusted EBITDA of $1.1 million for the quarter, representing another important milestone in our pathway to profitability initiative.

"Our strong year-to-date performance, combined with expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and continued demand for MVE's industry-leading products, gives us confidence in our outlook. As a result, we are increasing our full-year 2026 revenue guidance to a range of $197 million to $199 million," concluded Mr. Shelton.

The following table presents Q3 2026 revenue compared with Q3 2025:  

Cryoport, Inc. and Subsidiaries
Revenue
Three Months Ended September 30, (unaudited) Nine Months Ended September 30, (unaudited)
(in thousands) 2026 2025 % Change 2026 2025 % Change
Life Sciences Services $   28,564 $   24,258 18 % $      83,431 $      71,492 17 %
BioLogistics Solutions 22,522 19,428 16 % 66,549 57,832 15 %
BioStorage/BioServices 6,042 4,830 25 % 16,882 13,660 24 %
Life Sciences Products $   21,656 $   19,975 8 % $      63,558 $      59,235 7 %
Total Revenue $   50,220 $   44,233 14 % $    146,989 $    130,727 12 %

BioLogistics Solutions revenue increased 16% year-over-year in Q3 2026, driven by continued commercial therapies development, and clinical trial progress within the CGT market.  BioStorage/BioServices revenue grew 25% year-over-year, reflecting another strong quarter of demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.

As of September 30, 2026, the number of commercial cell and gene therapies we support increased to 23 and our total global clinical trial count that we support rose to 788 clinical trials, a net increase of 43 clinical trials over September 30, 2025, with 99 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:

Cryoport Supported Clinical Trials by Phase Cryoport Supported Clinical Trials by Region
Clinical Trials September 30, Clinical Trials September 30,
2024 2025 2026 2024 2025 2026
Phase 1 295 309 319 Americas 531 559 589
Phase 2 317 353 370 EMEA 112 137 143
Phase 3 79 83 99 APAC 48 49 56
Total 691 745 788 Total 691 745 788

In Q3 2026, Cryoport's customer, Replimune, received accelerated U.S. Food and Drug Administration (FDA) approval for TUDRIQEV™ for the treatment of adults with unresectable advanced cutaneous melanoma, a skin cancer that has spread too widely or deeply to be safely or completely removed with surgery. Also, during the quarter Crispr Therapeutics and their partner Vertex Pharmaceuticals received FDA supplemental approval to expand the label of CASGEVY® for treatment of people 2 years of age and older with either Sickle Cell Disease (SCD) or Transfusion-dependent Beta Thalassemia (TDT).  CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT . 

Two of Cryoport's customers filed Biologics License Applications (BLA) with the FDA in the third quarter and we anticipate another five possible BLA or Marketing Authorization Applications (MAA) in 2026.  Cryoport also anticipates two possible additional new therapy approvals (both of which have received Prescription Drug User Fee Act (PDUFA) dates from the FDA for Q4 2026), and one possible additional supplemental approval for geographic expansion from our customer base this year.

Operational Milestones

  • Cryoport Systems initiated BioLogistics services at its new state-of-the-art Global Supply Chain Center located in Santa Ana, California.
  • Cryoport Systems' Global Supply Chain Center in Paris, France, received ISO 9001 and ISO 21973 certifications. ISO 21973 certification is the first international standard developed specifically to address the transportation risks associated with human cells for therapeutic use.
  • CRYOGENE secured new BioStorage and service contracts with customers including Houston Methodist Medical Center, Sonic Clinical Trials, and XenoSTART.

Financial Highlights

On June 11, 2025, the Company completed the divestiture of its CRYOPDP specialty courier business to DHL Group. The results of CRYOPDP, a former business within Cryoport's Life Sciences Services segment, are presented as discontinued operations for all periods and are excluded from the non-GAAP financial measures in this release.

Revenue

  • Total revenue for Q3 2026 was $50.2 million, compared to $44.2 million for Q3 2025, a year-over-year increase of 14%, or $6.0 million.
    • Life Sciences Services revenue for Q3 2026 (representing 57% of our total revenue) was $28.6 million, compared to $24.3 million for Q3 2025, up 18% year-over-year, including BioStorage/BioServices revenue of $6.0 million, up 25% year-over-year.
    • Life Sciences Products revenue for Q3 2026 (representing 43% of our total revenue) was $21.7 million, compared to $20.0 million for Q3 2025.
  • Total revenue for 9M 2026 was $147.0 million, compared to $130.7 million for 9M 2025.
    • Life Sciences Services revenue for 9M 2026 was $83.4 million, compared to $71.5 million for 9M 2025, including BioStorage/BioServices revenue of $16.9 million, compared to $13.7 million for 9M 2025.
    • Life Sciences Products revenue for 9M 2026 was $63.6 million, compared to $59.2 million for 9M 2025.

Gross Margin

  • Total gross margin was 47.5% for Q3 2026, compared to 48.2% for Q3 2025.
    • Gross margin for Life Sciences Services was 50.4% for Q3 2026, compared to 49.7% for Q3 2025.
    • Gross margin for Life Sciences Products was 43.6% for Q3 2026, compared to 46.4% for Q3 2025.
  • Total gross margin was 46.7% for 9M 2026, compared to 46.9% for 9M 2025.
    • Gross margin for Life Sciences Services was 49.7% for 9M 2026, compared to 48.8% for 9M 2025.
    • Gross margin for Life Sciences Products was 42.6% for 9M 2026, compared to 44.6% for 9M 2025.

Operating Costs and Expenses

  • Operating costs and expenses were $32.6 million for Q3 2026, compared to $31.3 million for Q3 2025. Operating costs and expenses were $97.0 million for 9M 2026, compared to $88.1 million for 9M 2025.

Loss from Continuing Operations

  • Loss from continuing operations was $10.9 million for Q3 2026, compared to a loss of $6.7 million for Q3 2025. Loss from continuing operations was $28.5 million for 9M 2026, compared to a loss of $25.4 million for 9M 2025.

Net Income (Loss) – including Discontinued Operations

  • Net loss was $10.9 million for Q3 2026, compared to net loss of $6.9 million for Q3 2025. Net loss for 9M 2026 was $29.7 million, compared to net income of $89.9 million for 9M 2025. Net income for 9M 2025 was primarily driven by the sale of our CRYOPDP specialty courier business during Q2 2025, which contributed $115.4 million, net of taxes, to income from discontinued operations.
  • Net loss attributable to common stockholders for Q3 2026 was $12.9 million, or $0.25 per share. Net loss attributable to common stockholders for 9M 2026 was $35.7 million, or $0.71 per share. This compares to net loss attributable to common stockholders of $8.9 million, or $0.18 per share, and net income attributable to common stockholders of $83.9 million, or $1.68 per share, for Q3 2025 and 9M 2025, respectively.

Adjusted EBITDA from Continuing Operations

  • Adjusted EBITDA from continuing operations was $1.1 million for Q3 2026, compared to a negative $0.6 million for Q3 2025. Adjusted EBITDA from continuing operations for 9M 2026 was $0.9 million, compared to a negative $4.4 million for 9M 2025.

Cash, Cash equivalents, and Short-Term Investments

  • Cryoport held $393.1 million in cash, cash equivalents, and short-term investments as of September 30, 2026.

Revenue Guidance for Full-Year 2026

  • The Company is providing updated full-year 2026 revenue guidance in the range of $197 million to $199 million. The Company's 2026 revenue guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of our control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.

Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.

Additional Information

Further information on Cryoport's financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport's financial performance are provided in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which is expected to be filed with the Securities and Exchange Commission ("SEC") on November 5, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport's website at www.cryoportinc.com .

Earnings Conference Call Information

IMPORTANT INFORMATION: In addition to the earnings release, a document titled "Cryoport Third Quarter 2026 in Review," providing a review of Cryoport's business update, will be issued at 4:05 p.m. ET on Thursday, November 5, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar .

Cryoport management will host a conference call at 5:00 p.m. ET on November 5, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company's reported results. A slide deck will accompany the call.

Conference Call Information

Date: Thursday, November 5, 2026
Time: 5:00 p.m. ET
Dial-in numbers: 1-800-717-1738 (U.S.), 1-646-307-1865 (International)
Confirmation code: Request the "Cryoport Call" or Conference ID: 1107312
Live webcast: 'Investor Relations' section at www.cryoportinc.com or click here. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com  for a limited time. To access the replay of the questions and answers click here . A dial-in replay of the call will also be available to those interested, until November 12, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1107312#.

About Cryoport, Inc.

Cryoport, Inc.  (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™__." 

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

October 22, 2026 8:00 am EDT Download as PDF

NASHVILLE, Tenn., Oct. 22, 2026 /PRNewswire/ -- Cryoport, Inc.

 (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2026 on Thursday, November 5, 2026 after U.S. markets close.

In addition to the earnings release, a document titled "Cryoport Third Quarter 2026 in Review", providing a review of Cryoport's key operational developments, business milestones and strategic initiatives, will be issued at 4:05 p.m. ET on Thursday, November 5, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar

.

Cryoport management will host a conference call the same day at 5:00 p.m. ET. The conference call will be in the format of a questions and answers session and will address questions members of the investment community have regarding the Company's reported results. A slide deck will accompany the call.

Conference Call Information

| --- | --- |

| Date: | Thursday, November 5, 2026 |

| Time: | 5:00 p.m. ET |

| Dial-in numbers: | 1-800-717-1738 (U.S.), 1-646-307-1865 (International) |

| Confirmation code: | Request the "Cryoport Call" or Conference ID: 1107312 |

| Live webcast: | 'Investor Relations' section at www.cryoportinc.com or click here. |

Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com

 for a limited time. To access the replay of the questions and answers click here

. A dial-in replay of the call will also be available to those interested, until November 12, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1107312#.

**About Cryoport, Inc

**Cryoport, Inc.

 (Nasdaq: CYRX), is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com

 or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc

 or @cryoport on X at www.x.com/cryoport

 for live updates.

**Forward-Looking Statements

**Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Prompts

CryoPort, Inc. (ticker CYRX), listed in United States.

ETFs Holding CryoPort, Inc.

ETF Weight in ETF Shares Market value As of
SCDS 0.17% 772 $ 15.239K Nov 17, 2026
VFMO 0.09% 109,993 $ 1.76M Aug 31, 2026
AVSC 0.07% 118,066 $ 2.338M Nov 16, 2026
RESM 0.04% 82 $ 1,287.40 Jun 30, 2026
DFAS 0.02% 302,400 $ 6.078M Nov 12, 2026
DXUV 0.01% 22,273 $ 447.687K Nov 12, 2026
DFAC 0.01% 250,001 $ 5.025M Nov 12, 2026
DFSU 0.00% 5,282 $ 106.168K Nov 12, 2026
DCOR 0.00% 58,946 $ 1.185M Nov 12, 2026
DFAU 0.00% 13,873 $ 278.847K Nov 12, 2026
DFUS 0.00% 18,293 $ 367.689K Nov 12, 2026
AVUS 0.00% 8,976 $ 177.725K Nov 16, 2026
AVSU 0.00% 134 $ 2,653.20 Nov 16, 2026